How the NIH Fuels Private Business

A new report details the ways in which the federal science agency boost the US economy by stimulating the private sector.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, US DEPARTMENT OF THE TREASURYResearch supported by the National Institutes of Health (NIH) added $69 billion to the US gross domestic product and supported 7 million jobs in 2011 alone, according to a new report released by United for Medical Research, a coalition of industry, academic, and society partners that advocates for robust NIH budgets. The report also highlights specific examples of NIH funding that helped private companies get off the ground to become thriving members of the biotechnology and pharmaceutical industries.

Signature Genomics, for example, is a company that started with a new technology—microarray comparative genomic hybridization—developed by two NIH-funded researchers at the University of California, San Francisco. After being licensed and sublicensed, the technology was purchased in 2010 by PerkinElmer for $90 million.

Another company, TomoTherapy Inc., has changed the way that cancer is treated with radiation. University of Wisconsin researcher Thomas Mackie, who was supported by NIH grants for years, founded the company in 1997 with colleague Paul Reckwerdt after refining a technology that could zap tumors with radiation in an even manner. Today TomoTherapy employs 1,100 people worldwide, and its fiscal year 2012 revenue exceeded $400 million.

“The fact is that the next big medical breakthrough, and the next billion-dollar business idea, may ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies